These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2325463)

  • 1. [Treatment of macroprolactinomas with delayed bromocriptine. Effectiveness of a single intramuscular injection].
    García-Luna PP; Leal-Cerro A; Pereira JL; Navarro E; Trujillo F; Cortés A; Villamil F; Acosta D; Santos C; Revuelta M
    Med Clin (Barc); 1990 Feb; 94(4):126-9. PubMed ID: 2325463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chiasmal herniation as a complication of bromocriptine therapy.
    Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
    J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study].
    Brue T; James-Deidier A; Louvet JP; Dewailly D; Roger P; Schlienger JL; Schaison G; Hartemann P; Jaquet P
    Ann Endocrinol (Paris); 1991; 52(4):273-82. PubMed ID: 1818531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macroprolactinomas as cause of delayed puberty. A report of two cases and effects of medical therapy.
    Minniti G; Jaffrain-Rea ML; Ferretti E; Gulino A; Tamburrano G
    Minerva Endocrinol; 1996 Jun; 21(2):67-71. PubMed ID: 8968149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Morphological changes in prolactinoma induced by bromocriptine treatment].
    Scanarini M
    Minerva Endocrinol; 1990; 15(1):13-5. PubMed ID: 2274009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case].
    García Calzado MC; Ruiz Buendía A
    Rev Clin Esp; 1992 Jun; 191(2):112-3. PubMed ID: 1502384
    [No Abstract]   [Full Text] [Related]  

  • 17. [Macroprolactinoma reduction and pregnancy induction with bromocriptine].
    Grimaldo J; López Espinoza E; Villanueva C; Verulo Reyes TB; Ayala AR
    Ginecol Obstet Mex; 1988 Aug; 56():213-7. PubMed ID: 3154241
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
    Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinemia and reproductive disorders--a profile from north east.
    Choudhury SD; Goswami A
    J Assoc Physicians India; 1995 Sep; 43(9):617-8. PubMed ID: 8773064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
    Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
    J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.